Skip to Main content Skip to Navigation
Journal articles

Real study: Re-treatment evaluated on visual acuity for Lucentis® in neovascular AMD [Real study : retraitement par Lucentis® dans la DMLA neovasculaire évalué sur l'acuité visuelle]

D. Bellocq F. de Bats Muriel Rabilloud 1 L. Kodjikian 2
1 Biostatistiques santé
Département biostatistiques et modélisation pour la santé et l'environnement [LBBE]
Abstract : Purpose: To assess the value of a monthly injection of Lucentis® until stable visual acuity (VA) is obtained for three consecutive months without exudation in patients with neovascular age macular degeneration (AMD). Methods: Prospective, single-center, non-controlled trial including naïve AMD patients with neovascularization. An assessment of VA and a spectral domain optical coherence tomography (SD-OCT) were performed at baseline and every month. Monthly injections of Lucentis® were performed over three months. The monthly injections were then continued until three consecutive stable VA results were obtained with no signs of exudation. Results: Fifteen out of the 21 patients included were anatomically good responders. A mean gain of +14Le (9) was obtained up to the point at which there was no exudation. There was no additional gain from this point until 3 consecutive stable VA results were obtained. During the PRN phase, an additional mean gain of +3.2Le (7.7) was obtained. Conclusion: This initial VA-guided regimen with ranibizumab might prevent the slight decrease in VA observed during the first year of PRN studies. © 2018 Elsevier Masson SAS
Document type :
Journal articles
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-01916267
Contributor : Laboratoire Mateis Connect in order to contact the contributor
Submitted on : Thursday, November 8, 2018 - 1:22:00 PM
Last modification on : Tuesday, July 20, 2021 - 5:20:07 PM

Identifiers

Citation

D. Bellocq, F. de Bats, Muriel Rabilloud, L. Kodjikian. Real study: Re-treatment evaluated on visual acuity for Lucentis® in neovascular AMD [Real study : retraitement par Lucentis® dans la DMLA neovasculaire évalué sur l'acuité visuelle]. Journal Français D'Ophtalmologie, Elsevier Masson, 2018, 41 (5), pp.397-401. ⟨10.1016/j.jfo.2017.10.014⟩. ⟨hal-01916267⟩

Share

Metrics

Record views

47